Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy
Clinical progression · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher clinical progression compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
- Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes onlyRR 1.26 [1.08, 1.45]6 studies · 2373 participantsModerate